SEQLL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 USD | 0.00% |
|
-23.53% | -68.52% |
| 04-10 | SeqLL Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | SeqLL Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Sales 2022 | 78.66K 6.3M | Sales 2023 | - | Capitalization | 1.57M 126M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -320M | Net income 2023 | -5M -400M | EV / Sales 2022 | 2.14 x |
| Net cash position 2022 | 3.29M 263M | Net Debt 2023 | 236K 18.93M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.84
x | P/E ratio 2023 |
-0.27
x | Employees | 7 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 56.24% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -23.53% | ||
| Current month | -56.52% | ||
| 1 month | -56.52% | ||
| 3 months | -70.65% | ||
| 6 months | -88.27% | ||
| Current year | -68.52% |
1 week
1.30
1.70
1 month
1.302.26
Current year
1.305.09
1 year
1.3035.36
3 years
1.30232.00
5 years
1.30232.00
10 years
1.30232.00
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Jones
CEO | Chief Executive Officer | 44 | 31/12/12 |
Frances Scally
DFI | Director of Finance/CFO | 57 | 08/08/22 |
Abhijeet Shinde
CTO | Chief Tech/Sci/R&D Officer | 43 | 30/04/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Douglas Miscoll
BRD | Director/Board Member | 63 | - |
Patrice Milos
BRD | Director/Board Member | 65 | 30/08/21 |
Daniel Jones
CEO | Chief Executive Officer | 44 | 31/12/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.3 | 0.00% | 102 |
| 25/04/24 | 1.3 | -2.99% | 374 |
| 24/04/24 | 1.34 | -4.96% | 1,000 |
| 23/04/24 | 1.41 | -2.08% | 912 |
| 22/04/24 | 1.44 | -15.29% | 3,155 |
Delayed Quote OTC Markets, April 26, 2024 at 03:08 pm
More quotes
SeqLL Inc. (SeqLL) is a life sciences instrumentation and research services company that is engaged in the development of scientific assets and intellectual property across multiple omics fields. The Company is engaged in the design, development and manufacturing of genetic analysis technologies. It leverages its True Single Molecule Sequencing (tSMS) technology, which enables researchers and clinicians to contribute advancements to scientific research and development. Its tSMS platform offers a single molecule solution for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing by performing detection of nucleic acids without the need for complex sample manipulation. Researchers using its platform can analyze billions of single molecules in a single experiment and generate reproducible data. Its single molecule platform combines a fluorescence-based optical detection apparatus with a precision microfluidics and thermal control system to perform sequencing-by-synthesis.
| 1st Jan change | Capi. | |
|---|---|---|
| -68.52% | 495K | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- SEQL Stock
